Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform.

Alzheimer's disease PET Phospho-tau Plasma biomarker Positron emission tomography pTau217

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
21 Oct 2024
Historique:
received: 16 04 2024
revised: 29 09 2024
accepted: 02 10 2024
medline: 23 10 2024
pubmed: 23 10 2024
entrez: 22 10 2024
Statut: aheadofprint

Résumé

Plasma phospho-tau 217 (pTau217) assays can accurately detect Alzheimer's disease (AD) pathology, but clinical application is limited by the need for specialised equipment. This study tests the performance of a plasma pTau217 assay performed on the Lumipulse-G® platform, that is in widespread clinical use, for selecting patients for therapy based on β-amyloid (Aβ) status and tau staging. Participants included 388 individuals with Plasma pTau217 had a high correlation with both Aβ Centiloid (r = 0.76) and tau SUVR Plasma pTau217, measured by the widely-available, fully-automated Lumipulse®, was a strong predictor of both Aβ and tau PET status and demonstrated strong predictive power in identifying individuals likely to benefit the most from anti-Aβ treatments. NHMRC grants 1132604, 1140853, 1152623 and AbbVie.

Sections du résumé

BACKGROUND BACKGROUND
Plasma phospho-tau 217 (pTau217) assays can accurately detect Alzheimer's disease (AD) pathology, but clinical application is limited by the need for specialised equipment. This study tests the performance of a plasma pTau217 assay performed on the Lumipulse-G® platform, that is in widespread clinical use, for selecting patients for therapy based on β-amyloid (Aβ) status and tau staging.
METHODS METHODS
Participants included 388 individuals with
FINDINGS RESULTS
Plasma pTau217 had a high correlation with both Aβ Centiloid (r = 0.76) and tau SUVR
INTERPRETATION CONCLUSIONS
Plasma pTau217, measured by the widely-available, fully-automated Lumipulse®, was a strong predictor of both Aβ and tau PET status and demonstrated strong predictive power in identifying individuals likely to benefit the most from anti-Aβ treatments.
FUNDING BACKGROUND
NHMRC grants 1132604, 1140853, 1152623 and AbbVie.

Identifiants

DOI: 10.1016/j.ebiom.2024.105405 PMID: 39437657
pubmed: 39437657
pii: S2352-3964(24)00441-9
doi: 10.1016/j.ebiom.2024.105405
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105405

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests CCR has received research grants from NHMRC, Enigma Australia, Biogen, Eisai and Abbvie. He is on the scientific advisory board for Cerveau Technologies and has consulted for Prothena, Eisai, Roche, and Biogen Australia. VLV has received a grant from NIA and is and has been a consultant or paid speaker at sponsored conference sessions for Eli Lilly, Life Molecular Imaging, ACE Barcelona, and BRI Japan. ES and AWB are employees of Abbvie. SML is a scientific advisor for Cytox Ltd. SA has received grants from NHMRC, MRFF, and NIH and consulting fees from Eisai Australia. SRS has received grants from NHMRC, Alzheimer's Association (USA), Alzheimer's Drug Discovery Foundation, and Bright Focus Foundation and had a paid role in MRFF Grant Assessment Committee. The other authors did not report any conflict of interest.

Auteurs

Azadeh Feizpour (A)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.

James David Doecke (JD)

The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia; Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia.

Vincent Doré (V)

Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia; The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia.

Natasha Krishnadas (N)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.

Kun Huang (K)

Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.

Pierrick Bourgeat (P)

The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia.

Simon Matthew Laws (SM)

Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, Edith Cowan University, Joondalup, Western Australia, Australia; Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.

Christopher Fowler (C)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Joanne Robertson (J)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Lucy Mackintosh (L)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Scott Ayton (S)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Ralph Martins (R)

Australian Alzheimer's Research Foundation, Nedlands, Perth, Australia.

Stephanie Ruth Rainey-Smith (SR)

Australian Alzheimer's Research Foundation, Nedlands, Perth, Australia; Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.

Kevin Taddei (K)

Australian Alzheimer's Research Foundation, Nedlands, Perth, Australia.

Larry Ward (L)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Eddie Stage (E)

AbbVie, North Chicago, IL, USA.

Anthony Wilson Bannon (AW)

AbbVie, North Chicago, IL, USA.

Colin Louis Masters (CL)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Jurgen Fripp (J)

The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia.

Victor Luis Villemagne (VL)

Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.

Christopher Cleon Rowe (CC)

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia; Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia. Electronic address: christopher.rowe@austin.org.au.

Classifications MeSH